Pedro Henrique de Lima Prata

MCU-PH

Université de Limoges
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Aplastic anemia (AA) transformation into myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) is associated with a dismal prognosis. Hematopoietic stem cell transplant offers the sole possibility of cure, but data on long-term survival are scarce. We retrospectively analyzed 270 patients transplanted for MDS, AML, or an isolated cytogenetic abnormality after a diagnosis of AA or paroxysmal nocturnal hemoglobinuria reported to the EBMT. The median age at transplantation was 39 years. The 5-year overall survival (OS) rate was 64%, unaffected by chromosome 7 abnormalities, age at transplant, sex, interval from clonal evolution to transplant, and intensity of conditioning regimen. The 5-year non-relapse mortality rates were 34% (95% CI, 25-42%) for MDS patients and 19% (95% CI, 7-31%) for AML patients and were higher following a myeloablative conditioning regimen. The five-year relapse rate was 12% (95% CI, 6-19%) for MDS and 22% (95% CI, 9-35%) for AML. Our study’s survival estimates reflect a younger cohort of patients, considering the bimodal distribution of aplastic anemia. Conditioning regimen intensity did not affect relapse. For MDS patients, pretreating before transplant did not improve survival nor reduce relapse. Transplantation is feasible and effective in achieving long-term survival for transplant-eligible post-AA myeloid neoplasm patients. MDS patients may benefit from upfront RIC transplant, limiting toxicity without higher relapse. Posttransplant maintenance therapies to reduce the relapse incidence among AML patients might be warranted.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

In the case of donor/recipient rhesus (Rh)-incompatibility after allogeneic hematopoietic stem cell transplantation (alloHSCT), the transfusion policy in France is to transfuse red blood cells (RBC) in the donor’s Rh phenotype from the day of transplantation, leading to a risk of allo-immunization, either of donor or recipient origin. In this single-center retrospective study, the incidence of donor/recipient Rh incompatibility was 7.1% over an eight-year period including 1 012 alloHSCT. Six of 58 evaluable patients (10.3%) developed alloantibodies to RBC antigens within one year of alloHSCT. None of these allo-immunizations were directed against the donor-mismatched Rh antigens and none of them could have been prevented by the transfusion of recipient and donor Rh-compatible RBC units. None of these allo-immunizations led to immune-mediated hemolytic anemia. These results show that, in the context of donor/recipient Rh incompatibility, the transfusion of packed RBC units in the donor’s Rh phenotype from the day of alloHSCT is feasible and not associated with a high risk of allo-immunization. The generalization of this strategy could also be discussed even when donor and recipient Rh phenotypes could be respected, to allow the preservation of units of infrequent phenotypes for other indications.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (10)

Nicolas Boissel

Université Paris Cité

FRANCE
View details

Didier Blaise

Professor of Medicine

Aix-Marseille University

FRANCE
View details

David Michonneau

Professor

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Jennifer Tjon

Hematologist/Associate Professor

Leiden University Medical Center

NETHERLANDS
View details

Christophe Antoniewski

Sorbonne Université

FRANCE
View details

Ludovic Deriano

Principal Investigator

Institut Pasteur

FRANCE
View details

Stéphanie Gachet

Chercheuse contractuelle

INSERM

FRANCE
View details

Gerard Socie

-

FRANCE
View details

Aaron Mendez-Bermudez

INSERM

FRANCE
View details

Simona Pagliuca

Faculty member / Enseignant-chercheur / Enseignante-chercheuse

Université de Lorraine

FRANCE
View details